Question normal

The American Enterprise Institute hosted a drug pricing webinar a few weeks ago where Scott Gottleib provided historical context around the use of discounts and rebates. He suggested that we instead, eliminate rebates and move back to a system of discounts, but allow for price discrimination between channels. That is, different discounts could be given to different payers based on the specific deal negotiated. If we combined this with authority for Medicare to negotiate prices, do you think this could provide additional transparency to drug pricing? Would this make competition worse or better? For those interested in watching the discussion, I found it to be very informative: aei.org/events/is-the-cure-wor...